Accelerate Diagnostics scheduled call to review 2022 first quarter results.

Rhea-AI Summary

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced a conference call to discuss its 2022 first quarter results on May 16, 2022, at 4:30 p.m. ET. The call aims to provide insights into the company's performance during the first quarter. Participants can access the audio webcast via ir.axdx.com and will be available for replay until August 15, 2022. The company focuses on in vitro diagnostics, particularly addressing antimicrobial resistance and sepsis, with systems that expedite identification and susceptibility testing.

Positive

• The conference call provides an opportunity for direct insights into the company's first-quarter performance.
• Accelerate's diagnostic systems deliver results 1 to 2 days faster than traditional methods, allowing timely treatment decisions.

Negative

• None.

TUCSON , April 29, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Monday, May 16, 2022, at 4:30 p.m. Eastern Time to review 2022 first quarter results.

To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available until August 15, 2022.

To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 0355137. International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference.

A replay of the call will be available by telephone at +1.877.344.7529 (U.S.) or +1.412.317.0088 (International) using the replay code 5137603 until June 6, 2022.

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antimicrobial resistance and sepsis. The Accelerate Pheno® system and Accelerate Arc™ system are designed to reduce the time clinicians must wait to determine the most optimal antibiotic therapy for bacteremic patients. These diagnostic systems are designed to serve clinical laboratories with automated solutions to expedite time to identification and antimicrobial susceptibility test (AST) results directly from positive blood culture samples. Multiple external studies have proven that Accelerate solutions deliver results 1 to 2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient's infection, days earlier.

The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" and diamond shaped logos and marks are registered trademarks of Accelerate Diagnostics, Inc.

For more information about the company, its products and technology, or recent publications, visit axdx.com.

SOURCE Accelerate Diagnostics, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/accelerate-diagnostics-scheduled-call-to-review-2022-first-quarter-results-301536020.html

SOURCE Accelerate Diagnostics, Inc.

FAQ

When is the Accelerate Diagnostics conference call for Q1 2022 results?

The conference call is scheduled for May 16, 2022, at 4:30 p.m. Eastern Time.

How can I listen to the Accelerate Diagnostics Q1 2022 results call?

You can listen to the call through the audio webcast at ir.axdx.com or by phone at +1.877.883.0383.

What is the focus of Accelerate Diagnostics?

Accelerate Diagnostics is dedicated to providing in vitro diagnostic solutions for antimicrobial resistance and sepsis.

What are the benefits of Accelerate's diagnostic systems?

Their systems reduce the time to identify optimal antibiotic therapy for patients, providing results 1 to 2 days faster than existing methods.

Until when will the replay of the conference call be available?

The replay will be available until June 6, 2022.